Who Optimizes SG&A Costs Better? CRISPR Therapeutics AG or Geron Corporation

Biotech Giants' SG&A Strategies: CRISPR vs. Geron

__timestampCRISPR Therapeutics AGGeron Corporation
Wednesday, January 1, 2014511400016758000
Thursday, January 1, 20151340300017793000
Friday, January 1, 20163105600018761000
Sunday, January 1, 20173584500019287000
Monday, January 1, 20184829400018707000
Tuesday, January 1, 20196348800020893000
Wednesday, January 1, 20208820800025678000
Friday, January 1, 202110280200029665000
Saturday, January 1, 202210246400043628000
Sunday, January 1, 20237616200069135000
Monday, January 1, 202472977000
Loading chart...

Infusing magic into the data realm

Optimizing SG&A Costs: A Tale of Two Biotech Giants

In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability and operational efficiency. Over the past decade, CRISPR Therapeutics AG and Geron Corporation have taken distinct paths in optimizing these costs. From 2014 to 2023, CRISPR Therapeutics AG saw a significant increase in SG&A expenses, peaking in 2021 with a 1,900% rise from 2014. This reflects their aggressive expansion and investment in cutting-edge gene-editing technologies. In contrast, Geron Corporation maintained a more conservative approach, with a modest 310% increase over the same period, indicating a focus on steady growth and cost control. By 2023, CRISPR's expenses were approximately 10% higher than Geron's, showcasing their differing strategies in navigating the biotech landscape. This comparison highlights the diverse approaches companies can take in managing operational costs while pursuing innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025